Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company's President and CEO Gilmore O'Neill, M.B., M.M.Sc., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.
馬薩諸塞州劍橋，2025年1月6日（全球新聞網）—— Editas Medicine, Inc.（納斯達克：EDIT）是一家領先的基因編輯公司，今天宣佈公司總裁兼首席執行官Gilmore O'Neill萬.b.萬.m.Sc.將於2025年1月15日（星期三）上午11:15（太平洋時間）/ 下午2:15（東部時間）在加州舊金山召開第43屆J.P. 摩根醫療會議進行演講。
A live webcast of the presentation will be available on the "Investors" section of the Editas Medicine website at . An archived replay will be available on the website for approximately 30 days following the presentation.
演講的網絡直播將在Editas Medicine網站的「投資者」部分提供。會後約30天，網站會提供演講的存檔回放。
About Editas Medicine
As a leading gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit .
關於Editas Medicine
作爲一家臨牀階段的基因編輯公司，Editas Medicine致力於將CRISPR/Cas12a和CRISPR/Cas9基因組編輯系統的力量和潛力轉化爲全球危重疾病患者的強有力治療方法，並發現、開發、製造和商業化廣泛的疾病類別的轉化性、持久性、精確基因組藥物。Editas Medicine是Broad Institute的 Cas12a專利組合和Broad Institute和哈佛大學的Cas9 專利組合的人類藥品的獨家許可證持有人。有關最新信息和科學報告，請訪問。
作爲一家領先的基因編輯公司，Editas Medicine專注於將CRISPR/Cas12a和CRISPR/Cas9基因組編輯系統的力量和潛力轉化爲一條強大的在體藥物研發管道，以幫助全球患有嚴重疾病的人們。Editas Medicine致力於發現、開發、製造和商業化轉變性、持久的精準在體基因編輯藥物，適用於廣泛的疾病類別。Editas Medicine是Broad Institute的Cas12a專利資產以及Broad Institute和哈佛大學的Cas9專利資產在人體藥物方面的獨佔許可持有者。有關最新信息和科學演示，請訪問。
CONTACT: Media and Investor Contact:
ir@editasmed.com
聯繫方式：媒體及投資者聯繫方式：
ir@editasmed.com
譯文內容由第三人軟體翻譯。
